

**Main topic**

<b>Renal cell carcinoma</b> H. Huland · R. Hautmann	
H. Huland · R. Hautmann <b>Editorial: 8<sup>th</sup> Heinrich-Warner-Foundation-Symposium</b>	S 117
S. Störkel <b>Molecular pathology of renal cell carcinoma</b>	S 118
B. Ljungberg <b>Prognostic factors in renal cell carcinoma</b>	S 119
H. Moch <b>Early and late genetic changes in clear cell renal carcinoma</b>	S 121
M. A. S. Jewett <b>Current limitations of radiofrequency ablation in renal cell carcinoma</b>	S 122
D. A. Swanson <b>Metastasectomy for renal cell carcinoma</b>	S 123
I. Frank · H. Zincke <b>Prediction of site-specific metastases in surgically treated nonmetastatic renal cell cancer. Changes of follow-up protocol</b>	S 125
E. Y. Song · M. R. Shurin · I. L. Tourkova · G. Chatta · G. V. Shurin <b>Human renal cell carcinoma inhibits dendritic cell maturation and functions</b>	S 128
J. H. Finke · C. Tannenbaum · W. Storkus · P. Rayman · T. Das · K. Biswas A. Richmond · C. Moon · M. Thornton · I. Gill · A. Novick · R. Bukowski <b>Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis</b>	S 131
D. J. Schendel · C. S. Falk · B. Frankenberger · E. Noessner · J. Schleypen · H. Pohla <b>The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients</b>	S 133
R. J. Motzer · M. Mazumdar <b>Predicting survival of patients with metastatic renal cell carcinoma</b>	S 135
J. A. Ellerhorst · W. H. Hildebrand · J. W. Cavett · M. A. Fernandez-Vina S. Hodges · N. Poindexter · H. Fischer · E. A. Grimm <b>HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC</b>	S 137
S. Pyrhönen <b>Interferon update</b>	S 137
U. Keilholz <b>Immunotherapy in non-renal carcinomas</b>	S 138
E. Huland · H. Heinzer · R. A. Jörres · D. Loppow · H. Huland <b>Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy</b>	S 140